Merck stated Sept. 14 it will get a $1 billion stake in Seattle Genetics, a Bothell, Wash.-based drugmaker focused on cancer treatments..
More articles on drug store: Trump indications brand-new officer order targeted at reducing drug pricesBaptist Health opens 2 new retail pharmaciesAstraZeneca resumes UK vaccine trial after stopping due to individuals unfavorable response.
The two drugmakers will co-develop Seattle Genetics ladiratuzumab vedotin, an investigational antibody drug in clinical trials for breast cancer and other solid tumors..
Maia Anderson –
Monday, September 14th, 2020
Under the deal, Seattle Genetics is qualified for progress-dependent payments of approximately $2.6 billion from Merck..
Seattle Genetics likewise gave Merck an unique license to advertise Tuksya, its drug designed to treat HER2-positive cancers. Under that offer, Seattle Genetics will get $125 million from Merck and is qualified for progress-dependent payments of as much as $65 million..
They will likewise check the drug in mix with Mercks cancer immunotherapy Keytruda..
Check out the full news release here..
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.